» Articles » PMID: 2230258

Occurrence of Groups A and B of Respiratory Syncytial Virus over 15 Years: Associated Epidemiologic and Clinical Characteristics in Hospitalized and Ambulatory Children

Overview
Journal J Infect Dis
Date 1990 Dec 1
PMID 2230258
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Over 15 years respiratory syncytial virus (RSV) isolates from 1209 hospitalized and ambulatory children were examined for strain group and in a subset for subgroup to determine the associated epidemiologic and clinical characteristics. Three patterns of yearly outbreaks existed: (1) strong predominance of group A strains (9 years with 83%-100% A strains), (2) relatively equal proportions of group A and B strains (4 years), and (3) strong predominance of group B strains (78%-85%) in 2 years, separated by a decade. The first pattern of highly dominant A strains occurred in cycles of 1 or 2 consecutive years with a single intervening year in which B strains were greater than or equal to 40% of the isolates. Subgroups A1 and A2 predominated, while B2, 3, and 4 occurred almost equally. A greater clinical severity for Group A strains was suggested by children with group A infections requiring intensive care significantly more often (15.4 vs. 8.3%, P = .008). Further, strongly dominant A strain years were associated with higher proportions of RSV admissions requiring intensive care (16.6% vs. 5.5%, P less than .01). Strains of subgroups A2 and B4 were more frequently found in hospitalized patients and A1 in outpatients, and the 2 years with the highest rates of intensive care admissions were those in which subgroup A2 dominated.

Citing Articles

[Vaccination against respiratory syncytial virus (RSV)-For the protection of infants and older adults].

Pley C, Kampmann B Inn Med (Heidelb). 2024; 65(11):1066-1075.

PMID: 39453450 DOI: 10.1007/s00108-024-01795-z.


Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.

Haeberer M, Mengel M, Fan R, Toquero-Asensio M, Martin-Toribio A, Liu Q Infect Dis Ther. 2024; 13(11):2395-2413.

PMID: 39395922 PMC: 11499554. DOI: 10.1007/s40121-024-01058-2.


RSV Risk Profile in Hospitalized Adults and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.

Haeberer M, Mengel M, Fan R, Toquero-Asensio M, Martin-Toribio A, Liu Q Infect Dis Ther. 2024; 13(9):1983-1999.

PMID: 39033476 PMC: 11343947. DOI: 10.1007/s40121-024-01021-1.


Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.

Nuttens C, Moyersoen J, Curcio D, Aponte-Torres Z, Baay M, Vroling H Infect Dis Ther. 2024; 13(8):1725-1742.

PMID: 38971918 PMC: 11266343. DOI: 10.1007/s40121-024-01012-2.


Association of disease severity and genetic variation during primary Respiratory Syncytial Virus infections.

Bender W, Zhang Y, Corbett A, Chu C, Grier A, Wang L BMC Med Genomics. 2024; 17(1):165.

PMID: 38898440 PMC: 11188216. DOI: 10.1186/s12920-024-01930-7.